Paclitaxel plus bevacizumab for metastatic breast cancer.

  title={Paclitaxel plus bevacizumab for metastatic breast cancer.},
  author={Antonio Rossi and Valter Torri and Cesare Gridelli},
  journal={The New England journal of medicine},
  volume={358 15},
  pages={1637; author reply 1637-8}
To the Editor: On the basis of an increase in progression-free survival of 5.9 months, Miller et al. (Dec. 27, 2007, issue)1 imply that the addition of bevacizumab to paclitaxel is a significant advance in the treatment of metastatic breast cancer. However, progression-free survival is an unreliable measure of benefit in metastatic cancer, and patients given bevacizumab do not live longer than patients given paclitaxel alone. Furthermore, it is questionable to cite response rates in phase 3… CONTINUE READING

From This Paper

Topics from this paper.
17 Citations
8 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 17 extracted citations

Similar Papers

Loading similar papers…